The present invention provides a fluorescent molecular probe for efficient fluorescent detection (visualization) of tumors or for implementing fluorescent detection and photodynamic treatment, more specifically, the present invention provides a macromolecular fluorescent molecular probe for fluorescent detection of tumor, comprising a complex comprising a fluorescent molecule and a biocompatible macromolecule.

Disclosed herein are semiconducting polymers of formula I and polymeric composite materials containing said polymer, where said polymer displays near-infrared afterglow luminescence. The polymers of formula I have the following structure:

##STR00001##

where n, m, o, p, A and R.sub.1 to R.sub.7 are as defined herein, and r is used to denote a random order to the repeating units.

A system for fluorescence guided surgery which includes alternatingly obtaining white light images and blue light images and simultaneously displaying those images on a display screen, such that a surgeon is presented with immediate, real-time video which shows the target tissue under white light and fluorescing tissue under blue light on the same screen, at the same time. The images may be presented side-by-side, or superimposed.

A method of treating a PSMA expressing cancer in a subject includes (a) administering to the subject a PSMA-targeted phthalocyanine conjugate compound having the formula (I), (b) detecting the PSMA-targeted phthalocyanine compound bound to and/or complexed with the prostate cancer cells to determine the location and/or distribution of the prostate cancer cells in the subject, (c) surgical resection of the detected cancer, and (d) irradiating the PSMA-targeted phthalocyanine compound at the site of surgical resection, thereby inducing the cytotoxic effects of the phthalocyanine compound on residual prostate cancer cells following surgical resection.

tion of heme oxygenase 1 (HO-1), in particular porphyrin, chlorin, bacteriochlorin or isobacteriochlorin compounds of formula I as defined herein having a tetrapyrrole or reduced tetrapyrrole backbone and a fluorophore. Such compounds can be used in the detection of HO-1 in vivo, ex vivo and in vitro, and can also be used in methods of diagnosis and as research reagents.

##STR00001##

The subject matter of the present invention is a compound characterized in that it has the general formula (I): in which P.sup.1, X, n, A, L and L.sub.1 are as defined in Claim 1. The present invention also relates to a process for preparing said compounds (I) and to the use thereof for targeting the cation-independent mannose 6-phosphate receptor (CI-M6PR). The subject matter of the invention is also a conjugate of formula (III): in which P.sup.1, X, n, A, L and L.sub.1 are as defined in Claim 6, and the use thereof: in a method for therapeutic treatment of the human or animal body, in particular chosen from enzyme replacement therapy, photodynamic therapy or cancer treatment, and/orin a method of diagnosis, in particular of diseases or of ailments associated with an increase or with a decrease in CI-M6PR expression. ##STR00001##

This disclosure provides IR700-molecule conjugates and methods of their use to remove (e.g., separate or isolate) a target from a sample in vivo or from a subject in vitro. It is shown herein that exposure of IR700 to near infrared (NIR) light removes a portion of IR700, changing it from a hydrophilic molecule, to one that is hydrophobic, resulting in aggregation of IR700 and anything bound to it. For example, the disclosed IR700-molecule conjugates and methods provide photo-controlled ways to control the pharmacokinetics of a drug in vivo, and can be used to remove undesired agents from environmental or food samples or to isolate target molecules in a laboratory.

Oxygen sensing luminescent dyes, polymers and sensors comprising these sensors and methods of using these sensors and systems are provided.

A method of assessing surgical margins is disclosed. The method includes, subsequent to administration of a compound configured to induce emissions of between about 600 nm and about 660 nm in cancerous tissue cells, positioning a distal end of a handheld, white light and fluorescence-based imaging device adjacent to a surgical margin. The method also includes, with the handheld device, substantially simultaneously exciting and detecting autofluorescence emissions of tissue cells and fluorescence emissions of the induced wavelength in tissue cells of the surgical margin. And, based on a presence or an amount of fluorescence emissions of the induced wavelength detected in the tissue cells of the surgical margin, determining whether the surgical margin is substantially free of at least one of precancerous cells, cancerous cells, and satellite lesions. The compound may be a non-activated, non-targeted compound such as ALA.

A method of preventing post-operative endophthalmitis involves injecting a colored antibiotic solution into the anterior segment of the eye during surgery, the antibiotic solution having moxifloxacin, cefuroxime, vancomycin, or some combination thereof, and the coloring agent being preferably a cobalamin (e.g., cyanocobalamin).